## **Resource Summary Report**

Generated by <u>NIF</u> on Apr 9, 2025

# **Metabolism and Transport Drug Interaction Database**

RRID:SCR\_006550 Type: Tool

### **Proper Citation**

Metabolism and Transport Drug Interaction Database (RRID:SCR\_006550)

### **Resource Information**

URL: http://www.druginteractioninfo.org/

Proper Citation: Metabolism and Transport Drug Interaction Database (RRID:SCR\_006550)

**Description:** The Database is a research and analysis tool developed at the University of Washington, in the Department of Pharmaceutics. It contains in vitro and in vivo information on drug interactions in humans from the following sources: \* 9648 peer-reviewed journal articles referenced in PubMed \* 102 New Drug Applications (NDAs) \* 411 excerpts of FDA Prescribing Information \* In-depth analyses of drug-drug interactions in the context of 40 diseases / co-morbidities. In addition, the database also provides PK Profiles of drugs, QT Prolongation data, including results of TQT studies from recent NDAs, as well as Regulatory Guidances and Editorial Summaries/Syntheses relevant to advances in the field of drug interactions. Access to the Database is licensed by UW Center for Commercialization (C4C) to organizations interested in in-depth information on drug interactions. The Database is particularly useful to scientists/clinicians working in drug discovery and drug development. Database users can search for information using several families of pre-formulated queries based on drug name, enzyme name, transporter name, therapeutic area, and more.

#### Abbreviations: DIDB

**Synonyms:** Metabolism Transport Drug Interaction Database, Drug Interaction Database, Metabolism & Transport Drug Interaction Database

Resource Type: database, data or information resource

Defining Citation: PMID:21106490

**Keywords:** drug, metabolism, pharmacokinetic, drug interaction, drug discovery, drug development

Funding:

Resource Name: Metabolism and Transport Drug Interaction Database

Resource ID: SCR\_006550

Alternate IDs: nlx\_149273

Record Creation Time: 20220129T080236+0000

Record Last Update: 20250409T060534+0000

### **Ratings and Alerts**

No rating or validation information has been found for Metabolism and Transport Drug Interaction Database.

No alerts have been found for Metabolism and Transport Drug Interaction Database.

### Data and Source Information

Source: SciCrunch Registry

### **Usage and Citation Metrics**

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at <u>NIF</u>.

Miyake T, et al. (2024) Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice. British journal of pharmacology, 181(7), 1091.

Miyake T, et al. (2021) Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice. British journal of pharmacology, 178(21), 4335.

Mori D, et al. (2020) Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs. Clinical pharmacology and therapeutics, 107(4), 1004.

Yu J, et al. (2020) In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018. Clinical and translational science, 13(4), 693.

Wu F, et al. (2020) Computational Approaches in Preclinical Studies on Drug Discovery and Development. Frontiers in chemistry, 8, 726.

McFeely SJ, et al. (2020) Variability in In Vitro OATP1B1/1B3 Inhibition Data: Impact of Incubation Conditions on Variability and Subsequent Drug Interaction Predictions. Clinical and translational science, 13(1), 47.

Filppula AM, et al. (2019) Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations. Scientific reports, 9(1), 5850.

McFeely SJ, et al. (2019) Drug-Drug Interactions of Infectious Disease Treatments in Low-Income Countries: A Neglected Topic? Clinical pharmacology and therapeutics, 105(6), 1378.

McFeely SJ, et al. (2019) Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3. Clinical and translational science, 12(4), 379.

Bernasconi C, et al. (2019) Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study. Toxicology in vitro : an international journal published in association with BIBRA, 60, 212.

Clerbaux LA, et al. (2018) Capturing the applicability of in vitro-in silico membrane transporter data in chemical risk assessment and biomedical research. The Science of the total environment, 645, 97.

Thiele I, et al. (2017) Quantitative systems pharmacology and the personalized drugmicrobiota-diet axis. Current opinion in systems biology, 4, 43.

Chapron A, et al. (2017) Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis. Clinical and translational science, 10(5), 395.

Zhang Y, et al. (2016) Extracting drug-enzyme relation from literature as evidence for drug drug interaction. Journal of biomedical semantics, 7, 11.

Wei X, et al. (2016) Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis. Journal of clinical pharmacology, 56(6), 693.

Yeung CK, et al. (2015) Organ Impairment-Drug-Drug Interaction Database: A Tool for Evaluating the Impact of Renal or Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs. CPT: pharmacometrics & systems pharmacology, 4(8), 489.

Wu HY, et al. (2013) An integrated pharmacokinetics ontology and corpus for text mining. BMC bioinformatics, 14, 35.

Quinney SK, et al. (2013) Integration of in vitro binding mechanism into the

semiphysiologically based pharmacokinetic interaction model between ketoconazole and midazolam. CPT: pharmacometrics & systems pharmacology, 2(9), e75.

Hazai E, et al. (2013) Predicting substrates of the human breast cancer resistance protein using a support vector machine method. BMC bioinformatics, 14, 130.

Hachad H, et al. (2010) A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database. Human genomics, 5(1), 61.